[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)].

指南 肺癌 医学 联想(心理学) 家庭医学 重症监护医学 内科学 病理 心理学 心理治疗师
出处
期刊:PubMed [National Institutes of Health]
卷期号:104 (34): 3175-3213 被引量:11
标识
DOI:10.3760/cma.j.cn112137-20240511-01092
摘要

To further standardize lung cancer prevention and treatment measures in China, enhance the quality of diagnosis and treatment, improve patient prognosis, and provide evidence-based medical guidance for clinicians at all levels, the Chinese Medical Association convened experts from respiratory medicine, oncology, thoracic surgery, radiotherapy, imaging, and pathology to develop the Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition). This consensus resulted in several updates from the 2023 edition. The 2024 guidelines highlight that the risk of lung cancer in smokers remains higher than that of non-smokers even 15 years after quitting. Additionally, a new lung cancer incidence risk model is expected to become a critical tool for screening high-risk groups. In pathology, the guidelines now include pathological evaluation of surgically resected lung cancer specimens following neoadjuvant therapy and suggest that immunohistochemical staining of certain transcription factors may aid in the classification of small cell lung cancer (SCLC). In molecular detection, the guidelines propose simultaneous detection of driver gene variations based on both RNA and DNA from specimens. The new edition also provides detailed descriptions of patient selection and surgical requirements for thoracic sub-lobectomy, aligned with the 9th TNM staging. Moreover, the guidelines expand treatment options, approving more therapies for immunoadjuvant and EGFR-TKI resistant lung cancer patients, as well as additional drug options for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations, EGFR 20 insertions, ALK fusions, and MET exon 14 skipping. These recommendations are based on state-approved drug applications, international guidelines, and current clinical practices in China, integrating the latest evidence-based medical research in screening, diagnosis, pathology, genetic testing, immune molecular marker detection, treatment methods, and follow-up care. The goal is to provide comprehensive and reasonable recommendations for clinicians, imaging specialists, laboratory technicians, rehabilitation professionals, and other medical staff at all levels.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lucia完成签到 ,获得积分10
1秒前
研友_VZG7GZ的应助被kiwi采纳,获得10
1秒前
ys发布了新的文献求助10
1秒前
778发布了新的文献求助10
2秒前
斯文败类的应助被耿春丽采纳,获得10
3秒前
3秒前
Viento完成签到 ,获得积分10
4秒前
John完成签到,获得积分10
4秒前
傢誠发布了新的文献求助10
4秒前
ys完成签到,获得积分10
5秒前
5秒前
6秒前
yhy完成签到,获得积分10
7秒前
JSM完成签到,获得积分10
7秒前
8秒前
8秒前
orixero的应助被Rr采纳,获得10
8秒前
李子完成签到,获得积分10
8秒前
Pxm发布了新的文献求助10
9秒前
10秒前
10秒前
吃花椒的汪汪完成签到,获得积分10
10秒前
Zaiye发布了新的文献求助10
11秒前
涓尘发布了新的文献求助10
11秒前
11秒前
12秒前
Drcai发布了新的文献求助10
13秒前
冰可乐完成签到,获得积分10
13秒前
N30发布了新的文献求助10
13秒前
Q_Q完成签到,获得积分10
14秒前
科研狗头军师完成签到 ,获得积分10
14秒前
阿泽完成签到,获得积分10
14秒前
15秒前
15秒前
Green完成签到,获得积分10
16秒前
大模型的应助被778采纳,获得10
16秒前
16秒前
17秒前
奋斗书竹发布了新的文献求助10
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187652
求助须知:如何正确求助?哪些是违规求助? 9575758
关于积分的说明 21842805
捐赠科研通 7785538
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559480
邀请新用户注册赠送积分活动 2481963